News

Octagam 10% [immune globulin intravenous (human) 10% (100mg/ml) liquid preparation] helps in rapidly raising platelet counts to control or prevent bleeding in chronic ITP patients. The FDA approval

Currently, nintedanib is under FDA and European Medicines Agency (EMA review) to be indicated for the treatment of IPF. Boehringer Ingelheim chief medical officer Klaus Dugi said the

The company is focused on developing first-in-class platform of therapeutics to address pain at its molecular roots. With ADYX-003, the company will build on the results of the

By using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology, the companies will seek to use the power of the body’s own immune system to attack

Imugene’ cancer immunotherapy vaccine candidate HER-Vaxx is scheduled to enter into a Phase I/II clinical trial in 2015. Under the deal, Mymetics will use its strong experience and

The Phase 1/2 study, taking place at Tampere Hospital in Finland, a world-leading site for celiac disease research, is a two-part (single and repeated administration), double-blind, placebo-controlled, dose

Basilea’s co-development partner Astellas Pharma Inc. also recently submitted a New Drug Application (NDA) for isavuconazole to the U.S. Food and Drug Administration (FDA). Ronald Scott, Basilea’s Chief

Previously, NexoBrid received marketing authorization from the European Medicines Agency for this same indication in the European Union (EU), and the product was commercially launched. "We are especially

ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve